Search Within

Mark Kris

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Journal Article (115)
  2. Meeting Abstract (107)
  3. Research Letter (1)
Groups
  1. Department of Medicine (223)
  2. GSK Faculty (223)
  3. Human Oncology and Pathogenesis Program (223)
  4. Solid Tumor Oncology Division (223)
  5. Thoracic Oncology (223)
  6. Department of Pathology and Laboratory Medicine (209)

More Groups

People
  1. Marc Ladanyi (189)
  2. Gregory Riely (128)
  3. Maria Arcila (96)
  4. Charles Rudin (63)
  5. Maureen Zakowski (63)
  6. Helena Yu (61)

More People

Years
  1. 2025 (1)
  2. 2024 (7)
  3. 2023 (11)
  4. 2022 (10)
  5. 2021 (8)
  6. 2020 (10)

More Years

Publications
  1. Journal of Clinical Oncology (68)
  2. Journal of Thoracic Oncology (38)
  3. Clinical Cancer Research (35)
  4. Cancer Discovery (7)
  5. Modern Pathology (7)
  6. Laboratory Investigation (6)

More Publications

Publishers
  1. American Society of Clinical Oncology (72)
  2. American Association for Cancer Research (47)
  3. Elsevier Inc. (44)
  4. Nature Publishing Group (10)
  5. Oxford University Press (10)
  6. Nature Research (7)

More Publishers

Results (223)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparison of the characteristics and clinical course of 677 patients with metastatic lung cancers with mutations in KRAS codons 12 and 13
    Meeting Abstract

    Yu, H. A.; Sima, C. S.; Shen, R. L.; Kass, S. L.; Kris, M. G.; Ladanyi, M.; Riely, G. J.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Response to erlotinib and prognosis for patients with de novo epidermal growth factor receptor (EGFR) T790M mutations
    Meeting Abstract

    Riely, G. J.; Yu, H. A.; Arcila, M. E.; Hellmann, M. D.; Ladanyi, M.; Kris, M. G.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Patterns of metastasis and survival in patients with PI3K pathway-driven stage IV squamous cell lung cancers (SQCLC)
    Meeting Abstract

    Paik, P. K.; Moreira, A. L.; Wang, L.; Won, H. H.; Hasanovic, A.; Rekhtman, N.; Sima, C. S.; Ladanyi, M.; Berger, M. F.; Kris, M. G.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A multicenter effort to identify driver mutations and employ targeted therapy in patients with lung adenocarcinomas: The Lung Cancer Mutation Consortium (LCMC)
    Meeting Abstract

    Johnson, B. E.; Kris, M. G.; Berry, L. D.; Kwiatkowski, D. J.; Iafrate, A. J.; Varella-Garcia, M.; Wistuba, I. I.; Franklin, W. A.; Ladanyi, M.; Su, P. F.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Screening for RET and ROS1 fusions in an enriched cohort of pan-negative never-smokers with advanced lung adenocarcinomas to identify patients for treatment in targeted therapy trials
    Meeting Abstract

    Drilon, A. E. D.; Wang, L.; Hasanovic, A.; Joubert, P.; Kris, M. G.; Riely, G. J.; Ladanyi, M.; Rizvi, N. A.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Comparison of the characteristics and clinical course of patients with metastatic KRAS mutant lung cancers
    Meeting Abstract

    Riely, G.; Yu, H. A.; Sima, C. S.; Shen, R. L.; Kass, S. L.; Kris, M. G.; Ladanyi, M.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Prospective molecular evaluation of small cell lung cancer (SCLC) utilizing the comprehensive mutation analysis Program at Memorial Sloan-Kettering Cancer Center (MSKCC)
    Meeting Abstract

    Pietanza, M. C.; Varghese, A.; Won, H.; Rekhtman, N.; Wang, L.; Travis, W. D.; Paik, P. K.; Riely, G. J.; Zakowski, M. F.; Ladanyi, M.; more...
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Patterns of metastasis and survival in patients with PI3K-aberrant and FGFR1 amplified stage IV squamous cell lung cancers (SQCLCs)
    Meeting Abstract

    Paik, P. K.; Moreira, A. L.; Wang, L.; Rekhtman, N.; Sima, C. S.; Won, H.; Ladanyi, M.; Berger, M. F.; Kris, M. G.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Treatment with therapies matched to oncogenic drivers improves survival in patients with lung cancers: Results from the Lung Cancer Mutation Consortium (LCMC)
    Meeting Abstract

    Kris, M. G.; Johnson, B.; Berry, L.; Kwiatkowski, D.; Iafrate, A. J.; Wistuba, I.; Varella-Garcia, M.; Franklin, W.; Aronson, S.; Su, P. F.; more...
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save
  • Ret fusion-positive advanced lung cancers: Response to first-line chemotherapy and survival in comparison to ROS1 and ALK fusion-positive and EGFR- and KRAS-mutant lung cancers
    Meeting Abstract

    Drilon, A.; Wang, L.; Joubert, P.; Snyder, A.; Cho, E. J.; Riely, G.; Kris, M.; Ladanyi, M.; Rizvi, N.
    Journal of Thoracic Oncology (2013)

    Fulltext@MSK | Save